tiprankstipranks
Trending News
More News >
Cytek Biosciences (CTKB)
NASDAQ:CTKB

Cytek Biosciences (CTKB) Stock Statistics & Valuation Metrics

Compare
58 Followers

Total Valuation

Cytek Biosciences has a market cap or net worth of $476.24M. The enterprise value is $1.09B.
Market Cap$476.24M
Enterprise Value$1.09B

Share Statistics

Cytek Biosciences has 126,659,195 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding126,659,195
Owned by Insiders9.19%
Owned by Institutions16.20%

Financial Efficiency

Cytek Biosciences’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is -4.92%.
Return on Equity (ROE)-0.02
Return on Assets (ROA)-0.01
Return on Invested Capital (ROIC)-4.92%
Return on Capital Employed (ROCE)-0.05
Revenue Per Employee302.34K
Profits Per Employee-9.08K
Employee Count663
Asset Turnover0.40
Inventory Turnover2.04

Valuation Ratios

The current PE Ratio of Cytek Biosciences is -140.81. Cytek Biosciences’s PEG ratio is -12.75.
PE Ratio-140.81
PS Ratio0.00
PB Ratio3.23
Price to Fair Value2.14
Price to FCF-62.15
Price to Operating Cash Flow-112.28
PEG Ratio-12.75

Income Statement

In the last 12 months, Cytek Biosciences had revenue of 200.45M and earned -6.02M in profits. Earnings per share was -0.05.
Revenue200.45M
Gross Profit111.11M
Operating Income-20.52M
Pretax Income-5.70M
Net Income-6.02M
EBITDA-10.03M
Earnings Per Share (EPS)-0.05

Cash Flow

In the last 12 months, operating cash flow was 21.30M and capital expenditures -3.76M, giving a free cash flow of 17.54M billion.
Operating Cash Flow21.30M
Free Cash Flow17.54M
Free Cash Flow per Share0.14

Dividends & Yields

Cytek Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.66
52-Week Price Change-40.77%
50-Day Moving Average3.23
200-Day Moving Average4.83
Relative Strength Index (RSI)52.17
Average Volume (3m)1.45M

Important Dates

Cytek Biosciences upcoming earnings date is Aug 12, 2025, After Close (Confirmed).
Last Earnings DateMay 8, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date

Financial Position

Cytek Biosciences as a current ratio of 5.86, with Debt / Equity ratio of 4.25%
Current Ratio5.86
Quick Ratio5.21
Debt to Market Cap<0.01
Net Debt to EBITDA8.14
Interest Coverage Ratio-3.92

Taxes

In the past 12 months, Cytek Biosciences has paid 320.00K in taxes.
Income Tax320.00K
Effective Tax Rate-0.06

Enterprise Valuation

Cytek Biosciences EV to EBITDA ratio is -76.34, with an EV/FCF ratio of 35.05.
EV to Sales3.82
EV to EBITDA-76.34
EV to Free Cash Flow35.05
EV to Operating Cash Flow30.18

Balance Sheet

Cytek Biosciences has $265.61M in cash and marketable securities with $7.45M in debt, giving a net cash position of -$258.17M billion.
Cash & Marketable Securities$265.61M
Total Debt$7.45M
Net Cash-$258.17M
Net Cash Per Share-$2.04
Tangible Book Value Per Share$2.75

Margins

Gross margin is 61.56%, with operating margin of -10.24%, and net profit margin of -3.00%.
Gross Margin61.56%
Operating Margin-10.24%
Pretax Margin-2.84%
Net Profit Margin-3.00%
EBITDA Margin-5.01%
EBIT Margin-10.24%

Analyst Forecast

The average price target for Cytek Biosciences is $5.75, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$5.75
Price Target Upside52.93% Upside
Analyst ConsensusModerate Buy
Analyst Count4
Revenue Growth Forecast-1.86%
EPS Growth Forecast-2.01%

Scores

Smart Score6
AI Score53
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis